Other researchers have disputed the FDA’s findings and to date there is no clear consensus. In a June 2014 drug safety communication, however, the FDA announced that the evidence was inconclusive and that it would not change its recommendation for use of Benicar. The FDA was prompted to conduct an analysis of the potential heart risks of olmesartan after two clinical trials that found that the drug could lead to an increased probability of sudden death, heart attacks, and strokes. Furthermore, since the symptom has been often confused for Celiac’s disease, many patients who suffer from sprue-like enteropathy did not receive a proper diagnosis.īenicar has also been associated with a higher risk of heart disease among patients with Type 2 diabetes. Tran and Hanlin Li, “Olmesarta and Drug-Induced Enterotaphy,” Pharmacy and Therapeutics 2014 39 (1): pp. Benicar -induced enteropathy can take as long as 1 year to fully develop, which means that the patient may begin to feel the side effects of Benicar after prolonged use of the drug (Tran H. Benicar has been shown to cause atrophy of the intestinal tract from patients taking the drug greater than 1 year who do NOT have Celiac disease.
Celiac disease is caused by an inability to digest gluten, sometimes called “gluten intolerance” - that results in the atrophy of the intestinal tract. In fact, many patients are misdiagnosed as having Celiac disease if the proper tests for Celiac disease are not performed.
Benicar causes an intestinal problem that has similar symptoms as Celiac’s disease. Some patients who have used Benicar for at least 1 year to treat high blood pressure have required extended hospitalization due to gastrointestinal side effects, including sprue-like enteropathy, malabsorption, malnutrition, chronic weight loss, dehydration, necessitating feeding tubes, renal failure from severe dehydration due to the small bowel injury. Reported side effects include chronic diarrhea, vomiting, extreme weight loss, malnutrition, and dehydration causing hospitalizations and debilitated states. Benicar is used to treat patients with high blood pressure, as it helps to narrow the blood vessels and improve the circulation of blood throughout the body. The drug has become the Japan-based pharmaceutical company’s highest selling product in the United States, with over ten million prescriptions written in 2012 alone. Other trade names the product is sold under include Tribenzor and Azor. Introduction to Benicar and its Side EffectsĪpproved by the Food and Drug Administration (FDA) in 2002, Benicar is an angiotensis II receptor blocker (ARB) manufactured by Sankyo that goes by the clinical name of olmesartan medoxomil. Having been heavily prescribed for over a decade, cases against Sankyo continue to mount as patients come forward to report adverse health effects that the manufacturer had failed to properly warn on. Furthermore, the company is accused of engaging in deceptive marketing practices and of understanding the true risks of the bowel injury adverse side effects of Benicar. Plaintiffs allege that Benicar was defectively designed and manufactured, as it has been associated with enteropathy (destruction of the small bowel). Benicar, a popular treatment for hypertension, has been the subject of multiple lawsuits filed against the prescription drug’s manufacturer, Daiichi Sankyo.
0 kommentar(er)
